| pubmed-article:11735244 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11735244 | lifeskim:mentions | umls-concept:C0001675 | lld:lifeskim |
| pubmed-article:11735244 | lifeskim:mentions | umls-concept:C0034693 | lld:lifeskim |
| pubmed-article:11735244 | lifeskim:mentions | umls-concept:C0029433 | lld:lifeskim |
| pubmed-article:11735244 | lifeskim:mentions | umls-concept:C0547047 | lld:lifeskim |
| pubmed-article:11735244 | lifeskim:mentions | umls-concept:C0757797 | lld:lifeskim |
| pubmed-article:11735244 | lifeskim:mentions | umls-concept:C2697525 | lld:lifeskim |
| pubmed-article:11735244 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:11735244 | pubmed:dateCreated | 2001-12-12 | lld:pubmed |
| pubmed-article:11735244 | pubmed:abstractText | The ability of the growth hormone secretagogue (GHS) Ipamorelin to counteract the catabolic effects of glucocorticoid (GC) on skeletal muscles and bone was investigated in vivo in an adult rat model. Groups of 8-month-old female rats were injected subcutaneously for 3 months with GC (methylprednisolone) 9 mg/kg/day or GHS (Ipamorelin) 100 microg/kg three times daily, or both GC and GHS in combination. The maximum tetanic tension of the calf muscles was determined in vivo in a materials testing machine. The maximum tetanic tension was increased significantly, and the periosteal bone formation rate increased four-fold in animals injected with GC and GHS in combination, compared with the group injected with GC alone. In conclusion, the decrease in muscle strength and bone formation found in GC-injected rats was counteracted by simultaneous administration of the growth hormone secretagogue. | lld:pubmed |
| pubmed-article:11735244 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11735244 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11735244 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11735244 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11735244 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11735244 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11735244 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11735244 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11735244 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11735244 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:11735244 | pubmed:issn | 1096-6374 | lld:pubmed |
| pubmed-article:11735244 | pubmed:author | pubmed-author:AndersenN BNB | lld:pubmed |
| pubmed-article:11735244 | pubmed:author | pubmed-author:OxlundHH | lld:pubmed |
| pubmed-article:11735244 | pubmed:author | pubmed-author:AndreassenT... | lld:pubmed |
| pubmed-article:11735244 | pubmed:author | pubmed-author:MalmlöfKK | lld:pubmed |
| pubmed-article:11735244 | pubmed:author | pubmed-author:JohansenP BPB | lld:pubmed |
| pubmed-article:11735244 | pubmed:author | pubmed-author:ØrtoftGG | lld:pubmed |
| pubmed-article:11735244 | pubmed:copyrightInfo | Copyright 2001 Harcourt Publishers Ltd. | lld:pubmed |
| pubmed-article:11735244 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11735244 | pubmed:volume | 11 | lld:pubmed |
| pubmed-article:11735244 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11735244 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11735244 | pubmed:pagination | 266-72 | lld:pubmed |
| pubmed-article:11735244 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:11735244 | pubmed:meshHeading | pubmed-meshheading:11735244... | lld:pubmed |
| pubmed-article:11735244 | pubmed:meshHeading | pubmed-meshheading:11735244... | lld:pubmed |
| pubmed-article:11735244 | pubmed:meshHeading | pubmed-meshheading:11735244... | lld:pubmed |
| pubmed-article:11735244 | pubmed:meshHeading | pubmed-meshheading:11735244... | lld:pubmed |
| pubmed-article:11735244 | pubmed:meshHeading | pubmed-meshheading:11735244... | lld:pubmed |
| pubmed-article:11735244 | pubmed:meshHeading | pubmed-meshheading:11735244... | lld:pubmed |
| pubmed-article:11735244 | pubmed:meshHeading | pubmed-meshheading:11735244... | lld:pubmed |
| pubmed-article:11735244 | pubmed:meshHeading | pubmed-meshheading:11735244... | lld:pubmed |
| pubmed-article:11735244 | pubmed:meshHeading | pubmed-meshheading:11735244... | lld:pubmed |
| pubmed-article:11735244 | pubmed:meshHeading | pubmed-meshheading:11735244... | lld:pubmed |
| pubmed-article:11735244 | pubmed:meshHeading | pubmed-meshheading:11735244... | lld:pubmed |
| pubmed-article:11735244 | pubmed:year | 2001 | lld:pubmed |
| pubmed-article:11735244 | pubmed:articleTitle | The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. | lld:pubmed |
| pubmed-article:11735244 | pubmed:affiliation | Department of Connective Tissue Biology, Institute of Anatomy, University of Aarhus, DK-8000 Aarhus C, Denmark. | lld:pubmed |
| pubmed-article:11735244 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11735244 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:11735244 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
